ERBB3 and neoplasm: Tumour specimens from HerGa treatments also exhibited downregulation of HER3 and the mitochondrial metabolic marker, TSPO, in contrast to S2Ga treatment (Supplementary Fig. 45), agreeing with the mitochondrial targeting of corroles once inside the tumour cell33.